Tanja Obradovic: Oncology Clinical Sites and Networks are Moving Toward Improved Capabilities
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn:
“Oncology clinical sites and networks are moving toward improved capabilities to meet the challenge of running increasingly complex trials including especially early phases that are bound to become even more elaborate due to emphasis on dosing optimization needs and critical role of biomarker-driven development.
Lates example just came few days ago with The START Center for Cancer Research (START), a leading global community-based early-phase oncology research network, announcing strategic partnership with Advarra, the provider of clinical research solutions for sites and institutions.
Advarra will provide end-to-end, patient-centric clinical trial workflow across its growing network of sites driving standardization, data efficiency, compliance, and consistent high quality. Systems company provides support for the link between all stakeholders including patients, sites, sponsors, and contract research organizations (CROs) toward more efficient operational execution.
These developments fall into increasing trend of US site networks growing capabilities to directly engage with Pharma and Biotech sponsors to streamline and accelerate early phase oncology development that may ultimately lead to lesser role of CROs in this cancer therapy development stage.”
More posts featuring Tanja Obradovic.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023